Pirfenidone is under clinical development by Yungjin Pharm and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pirfenidone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pirfenidone overview

Pirfenidone (YPI-010) is under development for the treatment of idiopathic pulmonary fibrosis.

Yungjin Pharm overview

Yungjin Pharm (Yungjin), subsidiary of KT&G Corp, is a pharmaceutical company. It develops, manufactures, and distributes active pharmaceutical ingredients, formulations, and tonic drinks. The company offers finished products for cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, pain and inflammatory disorders, nutritional supplement, and urology. It also provides vitamins and minerals products such as CoQ10/Multi-vitamins/Minerals tab, Multi-vitamins/Minerals tablet, Multi-vitamins(for pediatric) syr, CoQ10/Multi-vitamins/Minerals soft capsule, Multi-vitamins/Minerals tablet, and Selenium/Multi-vitamins/Minerals soft capsule. Yungjin also provides antibiotics and analgesics, anti-histamine, anti-fungal, total nutrition, vitamin and supplement and cosmetics, among others. The company also develops tonic drinks with pidotimod liquid. It operates through research and development institute, and factory located in Korea. Yungjin is headquartered in Seoul, South Korea

For a complete picture of Pirfenidone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.